Sodium butyrate is incorporated into central metabolism in fly head while inducing oxygen consumption increase.

Autor: Müller-Eigner A; Research Group Energy Metabolism and Epigenetics, Research Institute for Farm Animal Biology (FBN), Dummerstorf, Germany., Gille B; Research Group Energy Metabolism and Epigenetics, Research Institute for Farm Animal Biology (FBN), Dummerstorf, Germany., Dethloff F; Max Planck Institute for Biology of Ageing, Cologne, Germany., Meng C; Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), School of Life Sciences, Technical University of Munich, Freising, Germany., Ludwig C; Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), School of Life Sciences, Technical University of Munich, Freising, Germany., Heiker JT; Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany., Giavalisco P; Max Planck Institute for Biology of Ageing, Cologne, Germany., Peleg S; Research Group Energy Metabolism and Epigenetics, Research Institute for Farm Animal Biology (FBN), Dummerstorf, Germany.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2024 Dec 19; Vol. 19 (12), pp. e0315892. Date of Electronic Publication: 2024 Dec 19 (Print Publication: 2024).
DOI: 10.1371/journal.pone.0315892
Abstrakt: Butyrate has been proposed as a drug therapy by acting as a lysine deacetylase (KDAC) inhibitor and elevating protein acetylation, in particular on histones. Nonetheless, recent studies suggest that tissues such as the gut can utilize butyrate as a metabolite. We have previously shown that the addition of butyrate induces a rapid increase of oxygen consumption in whole Drosophila melanogaster heads. Here we show that while head oxygen consumption is increased by the addition of butyrate, no apparent changes are observed on the proteome and acetylome. Instead, we show that butyrate is metabolized and incorporated into the tricarboxylic acid (TCA) cycle. Collectively our data supports the notion that the therapeutic benefits of acute butyrate treatment may be also mediated by improving metabolic rates, rather than solely targeting the epigenome or acetylome.
Competing Interests: Shahaf Peleg is a co-founder of Luminova Biotech. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
(Copyright: © 2024 Müller-Eigner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje